Read by QxMD icon Read

Diabetes Technology & Therapeutics

Halis Kaan Akturk, Janet K Snell-Bergeon, Amanda Rewers, Leslie J Klaff, Bruce W Bode, Anne L Peters, Timothy S Bailey, Satish K Garg
BACKGROUND: The majority of therapies have generally targeted fasting glucose control, and current mealtime insulin therapies have longer time action profiles than that of endogenously secreted insulin. The primary purpose of this study was to assess both glucose time-in-range (TIR: 70-180 mg/dL) and postprandial glucose excursions (PPGE) in 1-4 h using a real-time continuous glucose monitor (CGM) with Technosphere insulin (TI) versus insulin aspart in patients with type 1 diabetes (T1DM) on multiple daily injections (MDI)...
September 15, 2018: Diabetes Technology & Therapeutics
Robert R Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B Zhuplatov, Traci Mansfield, David Klein, Arie Katz
BACKGROUND: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM). METHODS: This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10 mg/d; n = 50) with placebo (n = 50) in adult patients with T2D uncontrolled (HbA1c 7...
September 14, 2018: Diabetes Technology & Therapeutics
Martin de Bock, Julie Dart, Michael Hancock, Grant Smith, Elizabeth A Davis, Timothy W Jones
This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard™ automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA1c ) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements...
September 11, 2018: Diabetes Technology & Therapeutics
Rahat Maitland, Nashita Patel, Suzanne Barr, Christina Sherry, Barbara Marriage, Paul Seed, Llenalia Garcia Fernandez, Jose M Lopez Pedrosa, Helen Murphy, Ricardo Rueda, Lucilla Poston
BACKGROUND: Obesity is a risk factor for gestational diabetes (gestational diabetes). Low-glycemic index diets attenuate hyperglycemia. We designed a study to determine whether a slow-digesting, low-glycemic load (SD-LGL) beverage improves glucose tolerance in obese pregnant women without GDM. METHODS: This was a 3-arm comparison study comparing the effects of an SD-LGL nutritional beverage (glycemic load [GL] 730), an isocaloric control beverage (GL 1124), and habitual diet on glycemia in obese pregnant women...
September 11, 2018: Diabetes Technology & Therapeutics
Kamuran Turksoy, Iman Hajizadeh, Nicole Hobbs, Jennifer Kilkus, Elizabeth Littlejohn, Sediqeh Samadi, Jianyuan Feng, Mert Sevil, Caterina Lazaro, Julia Ritthaler, Brooks Hibner, Nancy Devine, Laurie Quinn, Ali Cinar
BACKGROUND: Exercise challenges people with type 1 diabetes in controlling their glucose concentration (GC). A multivariable adaptive artificial pancreas (MAAP) may lessen the burden. METHODS: The MAAP operates without any user input and computes insulin based on continuous glucose monitor and physical activity signals. To analyze performance, 18 60-h closed-loop experiments with 96 exercise sessions with three different protocols were completed. Each day, the subjects completed one resistance and one treadmill exercise (moderate continuous training [MCT] or high-intensity interval training [HIIT])...
September 6, 2018: Diabetes Technology & Therapeutics
Zheng Kang Lum, Wei Yann See Toh, Sze Mian Lim, Khairul Dzakirin Bin Rusli, Shaikh Abdul Kader Kamaldeen Abdul Shakoor, Keith Yu Kei Tsou, Daniel Ek Kwang Chew, Rinkoo Dalan, Sing Cheer Kwek, Noorani Othman, Joyce Xia Lian, Joyce Yu-Chia Lee
Empowerment plays significant roles in the complex management of type 2 diabetes. International guidelines have provided recommendations on management of Muslims who fast during Ramadan. However, there remains a lack of patient-centered epistemic tool to empower healthcare providers and patients in managing diabetes during Ramadan. This study discussed the development and evaluation of such tool. The collaborative algorithm was developed with reference to the nominal group technique by a board-certified clinical pharmacist and discussed with endocrinologists, nurses, and family physicians...
September 6, 2018: Diabetes Technology & Therapeutics
Michael P Stone, Pratik Agrawal, Xiaoxiao Chen, Margaret Liu, John Shin, Toni L Cordero, Francine R Kaufman
Real-world data from the first 3141 patients who completed 3 months of SmartGuard™ Auto Mode-enabled MiniMed™ 670G system use during the MiniMed 670G System Commercial Launch are reported. CareLink™ system data uploaded by real-world patients in the Commercial Launch from March 17, 2017 to December 31, 2017 were deidentified and analyzed. Comparisons of overall and night (10:00 PM-07:00 AM) time spent below, within, and above target glucose range (TIR) (70-180 mg/dL) between the baseline Manual Mode and closed-loop Auto Mode periods were made...
August 30, 2018: Diabetes Technology & Therapeutics
Yuki Sugiyama, Ryo Wakabayashi, Masatoshi Urasawa, Yuki Maruyama, Sari Shimizu, Mikito Kawamata
BACKGROUND: The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS: Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and cardiac surgery patients (n = 15), were enrolled. A subcutaneous sensor of the MiniMed™ 620G SCGM system was inserted into the upper arm...
August 28, 2018: Diabetes Technology & Therapeutics
Takeshi Osonoi, Maki Gouda, Mamiko Kubo, Kenji Arakawa, Toshio Hashimoto, Masanori Abe
BACKGROUND: Albuminuria characterizes the progression of kidney injury. The effect of canagliflozin on the excretion of microalbumin was assessed for investigating its renoprotective potential in Japanese patients with type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: Twenty Japanese patients with T2DM and microalbuminuria were enrolled and administered with 100 mg of canagliflozin once a day for 12 weeks. These subjects were admitted to the clinic at the start and end of the treatment period for 24-h urine collection...
August 10, 2018: Diabetes Technology & Therapeutics
Xiaoling Cai, Xueying Gao, Wenjia Yang, Linong Ji
BACKGROUND: As initial combination therapy of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitor, the efficacy and safety for the use of high dose of metformin or low dose of metformin and the efficacy and safety for the combination use for Asian and Caucasian patients were not clear. METHODS: Double-blind randomized controlled trials comparing the efficacy of initial combination therapy of metformin and DPP-4 inhibitors with metformin monotherapy were included...
August 10, 2018: Diabetes Technology & Therapeutics
Ryo Shibusawa, Eijiro Yamada, Shuichi Okada, Yasuyo Nakajima, Claire C Bastie, Masanobu Yamada
BACKGROUND: The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS: We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS: The overall glycemic control of patients who underwent CGM improved significantly; however, that of patients maintaining the same medications did not improve overall. Thirty-one patients with unchanged medications were divided into improved (n = 12) versus nonimproved (n = 19) groups...
September 2018: Diabetes Technology & Therapeutics
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne
No abstract text is available yet for this article.
September 2018: Diabetes Technology & Therapeutics
Di Sun, Xu Zhang, Xiu-Xin Hou
BACKGROUND: The purpose of this study was to compare the efficacy and safety of intensive insulin therapy (premixed insulin lispro vs. insulin glargine) in patients with type 2 diabetes mellitus (T2DM). METHODS: MEDLINE, EMBASE, the Cochrane Library, and were systematically searched for randomized clinical trials (RCTs) of patients with T2DM treated with either premixed insulin lispro or insulin glargine for a duration of 24 weeks. RESULTS: A total of 13 RCTs and 5401 patients were included in this study...
September 2018: Diabetes Technology & Therapeutics
Cindy Park, Quang A Le
BACKGROUND: Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize current evidence of effectiveness of CGM in adults with type 2 diabetes. MATERIALS AND METHODS: Cochrane, Embase, PubMed, and Web of Science were searched to include all studies that reported effectiveness of CGM in terms of HbA1c in adults aged 18 and older, with type 2 diabetes, on any treatment for diabetes...
September 2018: Diabetes Technology & Therapeutics
Bahira Shahim, Barbro Kjellström, Viveca Gyberg, Catriona Jennings, Stina Smetana, Lars Rydén
BACKGROUND: Point-of-care equipment for measuring glucose saves time and costs for both patients and professionals and minimizes preanalytic errors when screening for or managing dysglycemia, that is, impaired glucose tolerance and type 2 diabetes. The accuracy of such devices has, however, been questioned compared with analyses at an accredited hospital laboratory. OBJECTIVE: To investigate the agreement between glucose measurements made by the point-of-care HemoCue® Glucose 201 RT System (HemoCue, Ängelholm, Sweden) and local hospital laboratories...
September 2018: Diabetes Technology & Therapeutics
Keiichi Torimoto, Yosuke Okada, Maiko Hajime, Kenichi Tanaka, Yoshiya Tanaka
BACKGROUND: The objective of this study was to determine the risk factors of hypoglycemia by evaluating the glycemic profile using continuous glucose monitoring (CGM) in patients with type 2 diabetes mellitus (T2DM). METHODS: The participants were 294 patients with T2DM who received inpatient diabetes education. The mean blood glucose (MBG), coefficient of variation (CV), mean postprandial glucose excursion, low blood glucose index (LBGI), and percentage of time with blood glucose (BG) at <70 mg/dL were measured on admission using CGM...
September 2018: Diabetes Technology & Therapeutics
Bruce A Buckingham, Mark P Christiansen, Gregory P Forlenza, R Paul Wadwa, Thomas A Peyser, Joon Bok Lee, Jason O'Connor, Eyal Dassau, Lauren M Huyett, Jennifer E Layne, Trang T Ly
BACKGROUND: This study assessed the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm using an investigational device in adults with type 1 diabetes in response to overestimated and missed meal boluses and extended boluses for high-fat meals. MATERIALS AND METHODS: A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient open-loop run-in phase. Adults aged 18-65 years with type 1 diabetes and HbA1c 6...
September 2018: Diabetes Technology & Therapeutics
Robert H Slover, Jeanie B Tryggestad, Linda A DiMeglio, Larry A Fox, Bruce W Bode, Timothy S Bailey, Ronald Brazg, Mark P Christiansen, Jennifer L Sherr, Eva Tsalikian, Kevin B Kaiserman, Ashley Sullivan, Suiying Huang, John Shin, Scott W Lee, Francine R Kaufman
BACKGROUND: This study evaluated the safety and performance of the Guardian™ continuous glucose monitoring (CGM) system in children and adolescents with type 1 diabetes (T1D). MATERIALS AND METHODS: Subjects 2-18 years of age (mean ± standard deviation [SD] 13.1 ± 3.9 years) with T1D and duration of diagnosis ≥1 year were enrolled at 11 sites in the United States and wore two Guardian Sensor 3 sensors in the abdomen and/or buttock. Sensors were connected to a transmitter paired with either a Guardian Connect system (i...
September 2018: Diabetes Technology & Therapeutics
Priya Prahalad, Ananta Addala, Bruce A Buckingham, Darrell M Wilson, David M Maahs
No abstract text is available yet for this article.
September 2018: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"